PJ, 8 November 2014, Vol 293, No 7835

Study shows why people with Down’s syndrome develop Alzheimer’s disease

A study finds the processes that lead to changes in the brains of people with Down’s syndrome are similar to the changes that cause dementia in Alzheimer’s patients.…

Diabetic wounds heal faster with deferoxamine patch

Researchers have developed a transdermal patch that delivers the small molecule deferoxamine to accelerate wound healing in diabetes.…

Mortality risk should be considered with choice of sulfonylurea drug

Some sulfonylurea drugs, such as gliclazide and glimepiride, are associated with a lower mortality risk than others.…

Thursday 27 November: SW Scotland

Local practice forum event, ‘Are you using standards and guidance to ensure patient centred professionalism in the delivery of care?’ The Gailes Restaurant, Marine Drive, Gailes, Ayrshire KA11 5AE. Event 7pm, buffet 6.30pm. Book via the RPS website.…

Colin Challinor dies

On 24 October, Colin Challinor MRPharmS, aged 75, of 17 Saunders Copse, Mayford, Woking GU22 0NS. Mr Challinor registered in 1961 and left the Society in 2009. …

Experimental drug holds promise for Ewing sarcoma patients

Strategy for interfering with DNA repair offers potential treatment for Ewing sarcoma.…

Thursday 27 November: Yorkshire

Local practice forum event, ‘Research Ready: Recognition, Support and Action’. University of Bradford, Richmond building, Richmond Road, Bradford, Yorkshire BD7 1DP. Event 7.30pm, buffet 7pm. Book via the RPS website.…

Timothy House dies

On 21 October, Timothy House MRPharmS, aged 63, of 1 Chaplains Close, Haverhill, Suffolk CB9 0DT. Mr House registered in 1973.…

Diabetes patients could be quizzed about driving habits during medication reviews

People with diabetes could be questioned about their driving habits as part of their medication review, under proposals contained in a report by the Transport Research Laboratory. …

Stronger warning on Iclusig blood clot risk

Warnings about the risks of developing a blood clot or blocked artery with Iclusig (ponatinib), a leukaemia treatment, are to be made more robust, following the results of a European Medicines Agency review.…